Form 4: Azenta SVP Granted 34,235 Restricted Stock Units

Azenta, Inc.'s SVP, General Counsel & Secretary, Ephraim Starr, was granted 34,235 restricted stock units, vesting over three years.

Summary

• Ephraim Starr, Senior Vice President, General Counsel & Secretary of Azenta, Inc. (AZTA), was granted 34,235 shares of common stock in the form of restricted stock units (RSUs).
• The transaction date for this grant was November 24, 2025.
• No amount was paid upon the grant of these RSUs.
• The number of RSUs granted was determined by dividing a target award value by the average closing price of Azenta's common stock over the 20 trading days ending on the grant date.
• The RSUs are subject to time-based vesting, with 33-1/3% vesting per year, commencing on November 24, 2026.
• Following this transaction, Ephraim Starr beneficially owns 72,014 shares of common stock directly.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a key executive is a standard compensation practice, aligning management's interests with shareholders and aiding retention. It's a routine event with a slightly positive implication for corporate governance and stability, but not a significant market moving event.

Positives

• The grant of restricted stock units aligns the interests of a key executive, Ephraim Starr, with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• This equity grant serves as a retention incentive, encouraging the executive to remain with Azenta, Inc. for the multi-year vesting period.
• The transaction is part of a standard executive compensation package, indicating stable corporate governance practices.

Negatives

• The future vesting of these RSUs will result in a minor dilution of existing shareholder equity as new shares are issued.

Risks

• The value of the restricted stock units upon vesting is dependent on the future market price of Azenta, Inc.'s common stock, exposing the recipient to market volatility.
• While not explicitly stated as a risk in the filing, the issuance of new shares upon RSU vesting can lead to minor dilution for existing shareholders.

Future Outlook

The grant of restricted stock units implies a future increase in Ephraim Starr's beneficial ownership of Azenta, Inc. common stock as the units vest annually over a three-year period, beginning November 24, 2026.

Industry Context

The grant of restricted stock units to a senior executive is a standard practice in the life sciences and technology sectors, aligning with common industry trends for executive compensation and retention strategies. This type of equity incentive is widely used to motivate long-term performance and ensure management's interests are aligned with shareholder value creation.

Comparison to Industry Standards

• RSU grants are a common form of equity compensation for executives across various industries, including technology and life sciences, where Azenta operates.
• The vesting schedule of 33-1/3% per year over three years is a typical structure designed to incentivize long-term performance and retention, consistent with practices at comparable companies.
• Companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies, which operate in similar life sciences and analytical instrument sectors, frequently utilize similar equity compensation plans for their senior leadership, making this grant align with general industry practices for executive incentive compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting of RSUs, but generally positive for aligning executive incentives with shareholder value.
• Employees (Executive): Positive impact on Ephraim Starr's compensation and long-term wealth accumulation, serving as a strong retention incentive.

Next Steps

• The restricted stock units will begin vesting on November 24, 2026, with 33-1/3% of the units vesting annually thereafter.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not present new information that would materially alter the fundamental investment thesis for Azenta, Inc. While it indicates good corporate governance in terms of executive alignment and retention, it is not a catalyst for a 'buy' or 'sell' recommendation. Investors should continue to 'hold' based on broader company fundamentals and market conditions.

Keywords

Azenta, AZTA, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Equity Grant, Corporate Governance, Ephraim Starr